Efficacy of Low Dose, SubQ Interleukin-2 (IL-2) to Expand Endogenous Regulatory T-Cells in Liver Transplant Recipients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02739412|
Recruitment Status : Completed
First Posted : April 15, 2016
Last Update Posted : December 19, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Liver Transplantation||Biological: Interleukin-2||Phase 2|
A common complication of organ transplantation is 'rejection' of the transplanted organ. This occurs when the body's immune system tries to attack (or reject) the transplanted organ.
Drugs known as immunosuppressants (anti-rejection medications) are prescribed for patients after transplantation to prevent rejection. But, anti-rejection medications are associated with significant side effects including high blood pressure, high blood sugars, and high cholesterol - all of which may increase the risk of heart and vascular complications. Anti-rejection medications also increase the long-term risk of some types of cancer.
Sometimes, liver transplant patients who stop taking anti-rejection medications do not experience rejection of their transplanted liver and the liver keeps working. These patients are said to "tolerate" the transplanted liver, and this condition is referred to as "tolerance". Doctors are working to learn more about why some liver transplant patients develop tolerance after receiving a transplant, while others do not.
Studies have shown that patients who develop "tolerance" have an increase in a type of immune cell called regulatory T-cells or "Tregs". This means Tregs may be important in preventing rejection of a transplanted organ.
Studies have also shown that a human cytokine (a type of protein), called interleukin-2 (IL-2) aids in increasing the number of Treg cells in the body, and IL-2 has been given to patients to successfully treat disorders of the immune system such as graft vs host disease - a serious condition sometimes seen in patients after bone marrow transplantation.
The purpose of this investigation is to study if low dose IL-2, given to liver transplant patients by subcutaneous (under the skin) injections, over a 4 week period of time, will cause an increase in the number of Treg cells in the blood.
In addition, investigators will learn about the kinds of side effects low dose IL-2 will cause and how severe those side effects will be.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||7 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Efficacy of Low Dose, Subcutaneous Interleukin-2 (IL-2) to Expand Endogenous Regulatory T-Cells in Liver Transplant Recipients|
|Actual Study Start Date :||November 2016|
|Actual Primary Completion Date :||July 2022|
|Actual Study Completion Date :||July 2022|
IL-2 (Interleukin-2; Aldesleukin; Proleukin) administered daily as a single subcutaneous injection 0.30 MIU per meter squared body surface area for a duration of 4 weeks.
Subjects will self-administer low dose IL-2 as subQ injection (0.30 MIU per meter squared body surface area) for 4 weeks.
- Regulatory T-Cell Count [ Time Frame: 12 weeks ]Peripheral Blood Mononuclear Cell Flow Cytometry
- Differential Immune Cell Count [ Time Frame: 12 Weeks ]Peripheral Blood Mononuclear Cell Flow Cytometry
- T-Cell Exhaustion Phenotyping [ Time Frame: 1 Day ]Peripheral Blood Mononuclear Cell Flow Cytometry
- Kidney Function Serum Panel (> 1.5 x Upper Limit Normal) [ Time Frame: 12 weeks ]eGFR, creatinine, pH, electrolytes
- Liver Function Serum Panel (> 2 x Upper Limit Normal) [ Time Frame: 12 weeks ]ALT, AST, AlkPhos, total Bilirubin
- Serious Adverse Events (SAEs) [ Time Frame: 12 weeks ]Simple absolute counts and frequency
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 65 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Adult liver transplant recipients 2-4 years post transplantation
- Male or female adult, age 18 - 65 years
- Stable dosage of suppressant therapy for 1 month prior to study.
- Recipient of multiple transplants (including solid organ, stem-cell, and bone marrow)
- Serum liver panel (ALT, AST, Alkaline Phosphatase and Total Bilirubin) > 2 x ULN,
- Serum creatinine > 1.5 x ULN,
- eGFR of < 40 ml/min,
- Detectable hepatitis viral load,
- Abnormal ECG with clinically significant findings per study physician's judgement,
- Active infection,
- Presence or history of autoimmunity disorders,
- Evidence of allograft rejection,
- Liver biopsy or fibroscan evidence of advanced stage liver fibrosis (> Stage 2 Fibrosis),
- Presence or history of cardiac or pulmonary disease,
- Pregnant or nursing (lactating) women,
- Health condition precludes participation in trial at study physician's judgment,
- Inability to give consent.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02739412
|United States, Massachusetts|
|Beth Israel Deaconess Medical Center|
|Boston, Massachusetts, United States, 02215|
|Principal Investigator:||Michael P Curry, MD||Beth Israel Deaconess Medical Center|
|Responsible Party:||Michael Curry, Professor of Medicine, Beth Israel Deaconess Medical Center|
|Other Study ID Numbers:||
|First Posted:||April 15, 2016 Key Record Dates|
|Last Update Posted:||December 19, 2022|
|Last Verified:||December 2022|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs